Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients
Atrial fibrillation (AF) carries an increased risk of ischaemic stroke, and oral anticoagulation with warfarin can reduce this risk. The objective of this study was to evaluate the association between time in therapeutic International Normalised Ratio (INR) range when receiving warfarin and the risk...
Gespeichert in:
| Veröffentlicht in: | Thrombosis and haemostasis Jg. 106; H. 5; S. 968 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Germany
01.11.2011
|
| Schlagworte: | |
| ISSN: | 0340-6245, 2567-689X, 2567-689X |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Atrial fibrillation (AF) carries an increased risk of ischaemic stroke, and oral anticoagulation with warfarin can reduce this risk. The objective of this study was to evaluate the association between time in therapeutic International Normalised Ratio (INR) range when receiving warfarin and the risk of stroke and mortality. The study cohort included AF patients aged 40 years and older included in the UK General Practice Research Database. For patients treated with warfarin we computed the percentage of follow-up time spent within therapeutic range. Cox regression was used to assess the association between INR and outcomes while controlling for patient demographics, health status and concomitant medication. The study population included 27,458 warfarin-treated (with at least 3 INR measurements) and 10,449 patients not treated with antithrombotic therapy. Overall the warfarin users spent 63% of their time within therapeutic range (TTR). This percentage did not vary substantially by age, sex and CHA2DS2-VASc score. Patients who spent at least 70% of time within therapeutic range had a 79% reduced risk of stroke compared to patients with ≤30% of time in range (adjusted relative rate of 0.21; 95% confidence interval 0.18-0.25). Mortality rates were also significantly lower with at least 70% of time spent within therapeutic range. In conclusion, good anticoagulation control was associated with a reduction in the risk of stroke. |
|---|---|
| AbstractList | Atrial fibrillation (AF) carries an increased risk of ischaemic stroke, and oral anticoagulation with warfarin can reduce this risk. The objective of this study was to evaluate the association between time in therapeutic International Normalised Ratio (INR) range when receiving warfarin and the risk of stroke and mortality. The study cohort included AF patients aged 40 years and older included in the UK General Practice Research Database. For patients treated with warfarin we computed the percentage of follow-up time spent within therapeutic range. Cox regression was used to assess the association between INR and outcomes while controlling for patient demographics, health status and concomitant medication. The study population included 27,458 warfarin-treated (with at least 3 INR measurements) and 10,449 patients not treated with antithrombotic therapy. Overall the warfarin users spent 63% of their time within therapeutic range (TTR). This percentage did not vary substantially by age, sex and CHA2DS2-VASc score. Patients who spent at least 70% of time within therapeutic range had a 79% reduced risk of stroke compared to patients with ≤30% of time in range (adjusted relative rate of 0.21; 95% confidence interval 0.18-0.25). Mortality rates were also significantly lower with at least 70% of time spent within therapeutic range. In conclusion, good anticoagulation control was associated with a reduction in the risk of stroke.Atrial fibrillation (AF) carries an increased risk of ischaemic stroke, and oral anticoagulation with warfarin can reduce this risk. The objective of this study was to evaluate the association between time in therapeutic International Normalised Ratio (INR) range when receiving warfarin and the risk of stroke and mortality. The study cohort included AF patients aged 40 years and older included in the UK General Practice Research Database. For patients treated with warfarin we computed the percentage of follow-up time spent within therapeutic range. Cox regression was used to assess the association between INR and outcomes while controlling for patient demographics, health status and concomitant medication. The study population included 27,458 warfarin-treated (with at least 3 INR measurements) and 10,449 patients not treated with antithrombotic therapy. Overall the warfarin users spent 63% of their time within therapeutic range (TTR). This percentage did not vary substantially by age, sex and CHA2DS2-VASc score. Patients who spent at least 70% of time within therapeutic range had a 79% reduced risk of stroke compared to patients with ≤30% of time in range (adjusted relative rate of 0.21; 95% confidence interval 0.18-0.25). Mortality rates were also significantly lower with at least 70% of time spent within therapeutic range. In conclusion, good anticoagulation control was associated with a reduction in the risk of stroke. Atrial fibrillation (AF) carries an increased risk of ischaemic stroke, and oral anticoagulation with warfarin can reduce this risk. The objective of this study was to evaluate the association between time in therapeutic International Normalised Ratio (INR) range when receiving warfarin and the risk of stroke and mortality. The study cohort included AF patients aged 40 years and older included in the UK General Practice Research Database. For patients treated with warfarin we computed the percentage of follow-up time spent within therapeutic range. Cox regression was used to assess the association between INR and outcomes while controlling for patient demographics, health status and concomitant medication. The study population included 27,458 warfarin-treated (with at least 3 INR measurements) and 10,449 patients not treated with antithrombotic therapy. Overall the warfarin users spent 63% of their time within therapeutic range (TTR). This percentage did not vary substantially by age, sex and CHA2DS2-VASc score. Patients who spent at least 70% of time within therapeutic range had a 79% reduced risk of stroke compared to patients with ≤30% of time in range (adjusted relative rate of 0.21; 95% confidence interval 0.18-0.25). Mortality rates were also significantly lower with at least 70% of time spent within therapeutic range. In conclusion, good anticoagulation control was associated with a reduction in the risk of stroke. |
| Author | Gallagher, A M van Staa, T-P Setakis, E Plumb, J M Clemens, A |
| Author_xml | – sequence: 1 givenname: A M surname: Gallagher fullname: Gallagher, A M organization: General Practice Research Database, Medicines and Healthcare products Regulatory Agency, London, UK – sequence: 2 givenname: E surname: Setakis fullname: Setakis, E – sequence: 3 givenname: J M surname: Plumb fullname: Plumb, J M – sequence: 4 givenname: A surname: Clemens fullname: Clemens, A – sequence: 5 givenname: T-P surname: van Staa fullname: van Staa, T-P |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21901239$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kE1LxDAQhoOsuB968yy5eapOkiZtjrKoKywIsoK3kqSpG7dNapMi--8tuJ4emHl4mXmXaOaDtwhdE7gjRMD9bkNIBjwDxtkZWlAuikyU8mOGFsByyATN-RwtY_wCICKX_ALNKZFAKJMLtH9z8RBxaHBMQzhYrHyNuzAk1bp0xCrGYJxKtsY_Lu1xHHXok-tUO4nJmaA-x1YlFzx2Hqs0uGnTOD249jTuJ1if4iU6b1Qb7dWJK_T-9Lhbb7Lt6_PL-mGbGcFpyrTi2hQamAWSy5opJgQQLRkriCyZZlY0VFNuNdRacM0pGFbmTaG54XUDdIVu_3L7IXyPNqaqc9HY6RxvwxgrCZQxKkQ5mTcnc9Sdrat-mP4ajtV_OfQX9k5ptw |
| CitedBy_id | crossref_primary_10_1016_j_acvd_2015_05_005 crossref_primary_10_1093_eurheartj_ehw210 crossref_primary_10_1016_j_amjcard_2014_12_022 crossref_primary_10_6061_clinics_2012_06_01 crossref_primary_10_1371_journal_pone_0144314 crossref_primary_10_1016_j_amjcard_2022_10_039 crossref_primary_10_1093_ejcts_ezw313 crossref_primary_10_1038_s41598_017_11683_2 crossref_primary_10_1161_STROKEAHA_114_005599 crossref_primary_10_1007_s40266_018_0551_5 crossref_primary_10_1097_FJC_0000000000000558 crossref_primary_10_1016_j_mayocp_2016_03_007 crossref_primary_10_1111_jth_12041 crossref_primary_10_1016_j_ijcard_2017_11_087 crossref_primary_10_1136_heartjnl_2012_301841 crossref_primary_10_1007_s11897_012_0125_5 crossref_primary_10_1161_CIRCULATIONAHA_115_019794 crossref_primary_10_2146_ajhp140752 crossref_primary_10_2217_pgs_12_124 crossref_primary_10_1007_s11239_018_01800_x crossref_primary_10_1016_j_thromres_2015_01_006 crossref_primary_10_1016_j_amjmed_2018_06_012 crossref_primary_10_1007_s11239_013_0900_5 crossref_primary_10_1016_j_jstrokecerebrovasdis_2014_03_011 crossref_primary_10_1007_s40256_014_0092_1 crossref_primary_10_1016_j_jns_2019_01_031 crossref_primary_10_1177_1076029615623378 crossref_primary_10_1586_erc_12_48 crossref_primary_10_1160_TH12_07_0463 crossref_primary_10_1016_j_jstrokecerebrovasdis_2015_05_017 crossref_primary_10_1160_TH11_11_0784 crossref_primary_10_1177_03913988221093089 crossref_primary_10_1016_j_hlc_2020_04_018 crossref_primary_10_1517_14740338_2015_973847 crossref_primary_10_1160_TH15_04_0350 crossref_primary_10_1016_j_amjmed_2015_05_036 crossref_primary_10_2217_cpr_13_7 crossref_primary_10_3310_hta19480 crossref_primary_10_3390_medicina55010015 crossref_primary_10_1016_j_jstrokecerebrovasdis_2019_05_017 crossref_primary_10_1007_s00392_016_1071_0 crossref_primary_10_1007_s00059_013_3792_4 crossref_primary_10_1007_s10840_016_0206_6 crossref_primary_10_1160_TH13_12_1032 crossref_primary_10_1371_journal_pone_0213517 crossref_primary_10_1016_j_ejim_2016_05_023 crossref_primary_10_1111_jcpt_12438 crossref_primary_10_1016_j_rec_2015_11_007 crossref_primary_10_1038_tpj_2015_16 crossref_primary_10_1016_j_ijcard_2014_04_179 crossref_primary_10_1160_TH11_08_0568 crossref_primary_10_1007_s00380_015_0749_y crossref_primary_10_1556_OH_2014_30021 crossref_primary_10_1186_1756_0500_7_891 crossref_primary_10_1111_jce_16537 crossref_primary_10_1177_1076029618798944 crossref_primary_10_1007_s00059_013_3940_x crossref_primary_10_1136_openhrt_2017_000682 crossref_primary_10_2217_cpr_12_75 crossref_primary_10_2147_TCRM_S476187 crossref_primary_10_1016_j_ijcard_2014_11_112 crossref_primary_10_1111_jcpt_13656 crossref_primary_10_1371_journal_pone_0125257 crossref_primary_10_3390_ijerph19031436 crossref_primary_10_3390_ijerph18052244 crossref_primary_10_1371_journal_pone_0266658 crossref_primary_10_1016_j_ijcard_2015_06_056 crossref_primary_10_1038_nrcardio_2014_190 crossref_primary_10_1160_TH12_10_0772 crossref_primary_10_1016_j_beha_2013_07_008 crossref_primary_10_1007_s11739_014_1065_8 crossref_primary_10_1016_j_carrev_2013_04_003 crossref_primary_10_1586_14779072_2014_896196 crossref_primary_10_3390_jcm12031080 crossref_primary_10_1016_S0140_6736_13_62376_4 crossref_primary_10_1007_s15006_017_0341_8 crossref_primary_10_1016_j_ihj_2015_10_380 crossref_primary_10_1007_s40256_019_00347_3 crossref_primary_10_1016_j_hfc_2015_08_021 crossref_primary_10_1016_j_jstrokecerebrovasdis_2017_02_022 crossref_primary_10_1097_HCO_0b013e3283540857 crossref_primary_10_1371_journal_pone_0074037 crossref_primary_10_1160_TH14_10_0859 crossref_primary_10_1016_j_ahj_2017_05_016 crossref_primary_10_1016_j_ccep_2013_10_005 crossref_primary_10_1111_bjh_15850 crossref_primary_10_1160_TH11_08_0580 crossref_primary_10_1016_j_ijcard_2018_08_091 crossref_primary_10_1016_j_jjcc_2013_11_015 crossref_primary_10_1097_MAJ_0000000000000209 crossref_primary_10_1093_eurheartj_ehs435 crossref_primary_10_1161_CIRCRESAHA_114_303211 crossref_primary_10_1016_j_healun_2015_10_002 crossref_primary_10_1016_j_hrthm_2014_01_031 crossref_primary_10_1371_journal_pone_0231565 crossref_primary_10_1111_jth_12497 crossref_primary_10_1161_STROKEAHA_114_006476 crossref_primary_10_1080_14740338_2017_1351542 crossref_primary_10_1093_eurheartj_ehu298 crossref_primary_10_1185_03007995_2016_1164676 crossref_primary_10_1007_s11606_014_2784_2 crossref_primary_10_1016_j_clinthera_2017_11_014 crossref_primary_10_1016_j_drudis_2017_05_010 crossref_primary_10_1186_s13063_022_06250_8 crossref_primary_10_3389_fphys_2018_01644 crossref_primary_10_1007_s00392_016_0999_4 crossref_primary_10_1186_s42444_021_00038_8 crossref_primary_10_1016_j_rce_2016_12_011 crossref_primary_10_1093_ehjqcco_qcaf028 crossref_primary_10_1016_j_repc_2016_06_004 crossref_primary_10_1016_j_repce_2016_07_002 crossref_primary_10_1007_s40256_013_0016_5 crossref_primary_10_1161_STROKEAHA_113_000883 crossref_primary_10_1186_s13063_020_04972_1 crossref_primary_10_18087_cardio_2019_6_n516 crossref_primary_10_1016_j_healun_2020_01_1330 crossref_primary_10_1016_j_recesp_2015_04_017 crossref_primary_10_1111_eci_12758 crossref_primary_10_3389_fphar_2023_1191608 crossref_primary_10_1007_s40273_014_0246_7 crossref_primary_10_1016_S0140_6736_13_62343_0 crossref_primary_10_1136_heartjnl_2012_302101 crossref_primary_10_17116_flebo20241802189 crossref_primary_10_1007_s00392_014_0797_9 crossref_primary_10_1016_j_rec_2016_03_009 crossref_primary_10_1378_chest_13_2976 crossref_primary_10_1038_srep20432 crossref_primary_10_1159_000517608 crossref_primary_10_1161_CIRCULATIONAHA_113_003132 crossref_primary_10_1080_14656566_2018_1537368 crossref_primary_10_1016_j_aprim_2016_11_015 crossref_primary_10_3810_hp_2013_02_1012 crossref_primary_10_1186_s43044_020_00105_w crossref_primary_10_1016_j_tcm_2014_10_017 crossref_primary_10_1586_17474086_2015_1111756 crossref_primary_10_1007_s15016_014_0844_9 crossref_primary_10_3390_jpm12030487 crossref_primary_10_1016_j_clinthera_2014_07_016 crossref_primary_10_1161_JAHA_117_006669 crossref_primary_10_1016_j_thromres_2017_03_002 crossref_primary_10_1160_TH12_06_0438 crossref_primary_10_1016_j_amjmed_2014_05_023 crossref_primary_10_1097_HCO_0000000000000065 crossref_primary_10_1016_j_jtcvs_2019_02_061 crossref_primary_10_1016_j_iccl_2014_07_003 crossref_primary_10_1093_ageing_afu074 crossref_primary_10_1016_j_ijcard_2015_08_074 crossref_primary_10_1016_j_hrthm_2017_11_026 crossref_primary_10_1016_j_medcle_2018_02_027 crossref_primary_10_1002_clc_22294 crossref_primary_10_1016_j_cjca_2013_03_009 crossref_primary_10_1016_j_jacep_2015_09_015 crossref_primary_10_1097_MAT_0000000000000449 crossref_primary_10_1177_1076029615584664 crossref_primary_10_1002_jac5_1484 crossref_primary_10_1160_TH16_03_0203 crossref_primary_10_3111_13696998_2013_877468 crossref_primary_10_1160_TH12_10_0715 crossref_primary_10_1016_j_medcle_2016_02_010 crossref_primary_10_1016_j_ijcard_2017_10_091 crossref_primary_10_1016_j_thromres_2017_07_007 crossref_primary_10_1160_TH12_01_0027 crossref_primary_10_1177_10760296211049786 crossref_primary_10_1016_S1878_6480_13_70887_5 crossref_primary_10_1016_j_ijcard_2014_11_182 crossref_primary_10_1016_j_thromres_2015_06_007 crossref_primary_10_1556_OH_2014_29792 crossref_primary_10_1517_14656566_2014_948418 crossref_primary_10_1016_j_clinthera_2015_09_005 crossref_primary_10_1093_eurjhf_hfs171 crossref_primary_10_1111_ijcp_12157 crossref_primary_10_1136_bmjopen_2014_005379 crossref_primary_10_1016_j_ijcard_2014_11_196 crossref_primary_10_1016_j_pcad_2015_07_003 crossref_primary_10_1007_s11936_013_0285_y crossref_primary_10_1160_TH14_12_1087 crossref_primary_10_1093_eurheartj_ehs253 crossref_primary_10_1161_JAHA_113_000088 crossref_primary_10_1016_j_ijcard_2012_09_187 crossref_primary_10_1080_10810730_2014_934934 crossref_primary_10_1016_j_ejim_2015_06_007 crossref_primary_10_1177_1074248413501392 crossref_primary_10_1016_j_ijcard_2017_04_092 crossref_primary_10_1016_j_ijcard_2017_02_127 crossref_primary_10_1177_1060028017721241 crossref_primary_10_1038_s41598_018_33531_7 crossref_primary_10_1016_j_ahj_2018_03_004 crossref_primary_10_1016_S0001_4079_19_31265_8 crossref_primary_10_1016_j_ijcard_2017_06_004 crossref_primary_10_1016_j_thromres_2014_03_052 crossref_primary_10_1007_s12170_019_0599_8 crossref_primary_10_1016_j_ijcard_2013_06_083 crossref_primary_10_1186_1477_9560_12_14 crossref_primary_10_1007_s11096_016_0357_7 crossref_primary_10_36290_vnl_2022_004 crossref_primary_10_1177_1076029620945039 crossref_primary_10_1002_pds_4194 crossref_primary_10_1160_TH13_11_0948 crossref_primary_10_1111_ejh_13130 crossref_primary_10_1016_j_ccl_2014_07_009 crossref_primary_10_1016_j_curtheres_2022_100670 crossref_primary_10_1016_j_ijcard_2015_11_158 crossref_primary_10_1160_TH12_11_0804 crossref_primary_10_1016_j_jacc_2015_01_049 crossref_primary_10_1371_journal_pone_0110900 crossref_primary_10_1016_j_thromres_2019_09_002 crossref_primary_10_1111_jth_15245 crossref_primary_10_1016_S1773_035X_19_30294_1 crossref_primary_10_1016_j_cjca_2015_06_025 crossref_primary_10_1016_j_rec_2015_04_017 crossref_primary_10_1160_TH16_10_0757 crossref_primary_10_1093_ijpp_riab041 crossref_primary_10_1016_j_rce_2014_10_009 crossref_primary_10_1007_s40266_013_0127_3 crossref_primary_10_1007_s12325_014_0124_x crossref_primary_10_1007_s12181_014_0613_9 crossref_primary_10_1093_eurheartj_ehu006 crossref_primary_10_1160_TH16_12_0961 crossref_primary_10_1586_14779072_2016_1116941 crossref_primary_10_1111_jth_13272 crossref_primary_10_1371_journal_pone_0164076 crossref_primary_10_1093_europace_euw295 crossref_primary_10_1378_chest_13_2103 crossref_primary_10_1016_j_mpmed_2014_07_013 crossref_primary_10_1111_joim_12001 crossref_primary_10_1161_CIRCULATIONAHA_117_031658 crossref_primary_10_1111_jth_12874 crossref_primary_10_1097_HPC_0000000000000347 crossref_primary_10_1371_journal_pone_0284425 crossref_primary_10_3390_ijerph18115700 crossref_primary_10_1002_joa3_12714 crossref_primary_10_1586_erc_12_148 crossref_primary_10_1517_14740338_2014_895321 crossref_primary_10_1093_eurheartj_suaa100 crossref_primary_10_1586_14779072_2013_815423 crossref_primary_10_5798_dicletip_1723175 crossref_primary_10_2174_1381612826666200531151823 crossref_primary_10_1007_s12325_012_0026_8 crossref_primary_10_1186_s12872_016_0326_z crossref_primary_10_1016_j_rceng_2016_12_007 crossref_primary_10_1161_CIRCHEARTFAILURE_114_001725 crossref_primary_10_1016_j_clinthera_2023_03_008 crossref_primary_10_1155_2018_8012747 crossref_primary_10_1007_s00392_013_0616_8 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1160/TH11-05-0353 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2567-689X |
| ExternalDocumentID | 21901239 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Department of Health – fundername: Medical Research Council |
| GroupedDBID | --- .55 .GJ 0R~ 0VX 123 1KJ 4.4 53G 5RE AAQQT ABJNI ABOCM ACGFO ACGFS ACNUY AENEX AFFNX AGCGI AHRSK ALMA_UNASSIGNED_HOLDINGS BR6 C45 CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P H13 J5H NPM OVD P2P RTC RTE SJN TEORI X7M ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c652t-ba5bc7b03e0149d3a36601b93371983b3e6f2b25eb0db65b520c384f7b5c5df02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 290 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000297563000028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0340-6245 2567-689X |
| IngestDate | Fri Jul 11 03:09:38 EDT 2025 Mon Jul 21 06:06:07 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c652t-ba5bc7b03e0149d3a36601b93371983b3e6f2b25eb0db65b520c384f7b5c5df02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 21901239 |
| PQID | 902332668 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_902332668 pubmed_primary_21901239 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-11-01 |
| PublicationDateYYYYMMDD | 2011-11-01 |
| PublicationDate_xml | – month: 11 year: 2011 text: 2011-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | Thrombosis and haemostasis |
| PublicationTitleAlternate | Thromb Haemost |
| PublicationYear | 2011 |
| References | 21947024 - Thromb Haemost. 2011 Nov;106(5):753-4 |
| References_xml | – reference: 21947024 - Thromb Haemost. 2011 Nov;106(5):753-4 |
| SSID | ssj0016495 |
| Score | 2.5116947 |
| Snippet | Atrial fibrillation (AF) carries an increased risk of ischaemic stroke, and oral anticoagulation with warfarin can reduce this risk. The objective of this... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 968 |
| SubjectTerms | Adult Aged Aged, 80 and over Anticoagulants - therapeutic use Atrial Fibrillation - blood Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Atrial Fibrillation - mortality Blood Coagulation - drug effects Databases as Topic Drug Monitoring - methods Female General Practice Humans International Normalized Ratio Kaplan-Meier Estimate Male Middle Aged Odds Ratio Proportional Hazards Models Risk Assessment Risk Factors Stroke - blood Stroke - etiology Stroke - mortality Stroke - prevention & control Time Factors Treatment Outcome United Kingdom Warfarin |
| Title | Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21901239 https://www.proquest.com/docview/902332668 |
| Volume | 106 |
| WOSCitedRecordID | wos000297563000028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07TwQhECa-Chsf8XW-QmFLXGFhdytjjOYaLxejyXYbhode1N3TPf39DhxnZyxsKAgQMgwzH8PAR8iZgZxbLjwrIZMMPb5m2ljPhOWZMxVYYSCSTRSjUVnX1Tjl5vQprXJhE6Ohtp0JMfLzCp0LQg1VXk7fWSCNCperiUFjmawKRDIho6uoIwedxO2vyqpepLqr7PxhGIKBkmUiECH_BiejW7nd_OeEtshGwpP0aq4A22TJtTvk-X7Sv_S087SffXQvjurW0rcItBF0U52WxFkawrC0_4QOLccbjoNyRtXQT4nUi05aqiOxB_XhbcBrqk6_sfa75PH25uF6yBKlAjNK8hkDLcEUkAkXjkZWaKHwRAaVEMVFVQoQTnkOXDrILCgJkmdGlLkvQBppfcb3yErbte6A0AIQWVlsqqo8oDrtpMoVmgOwvrQXdkDoQm4Nqmy4h9Ct6z775kdyA7I_l30znX-t0fCAT7ioDv_ufETWY3w3vgs8Jqset6s7IWvmazbpP06jKmA5Gt99A--swsk |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risks+of+stroke+and+mortality+associated+with+suboptimal+anticoagulation+in+atrial+fibrillation+patients&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Gallagher%2C+A+M&rft.au=Setakis%2C+E&rft.au=Plumb%2C+J+M&rft.au=Clemens%2C+A&rft.date=2011-11-01&rft.issn=2567-689X&rft.eissn=2567-689X&rft.volume=106&rft.issue=5&rft.spage=968&rft_id=info:doi/10.1160%2FTH11-05-0353&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon |